Search for Unknown Tumor-Antagonizing Genes

Genes Chromosomes and Cancer

Volumn 38, Issue 4, 2003, Pages 307-321

  Imreh, Stephan ^a   Klein, George ^a   Zabarovsky, Eugene R ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CX3C; DELETED IN LUNG CANCER 1 PROTEIN; FYVE AND COILED COIL DOMAIN CONTAINING 1 PROTEIN; LACTOFERRIN; LAMININ RECEPTOR; LEUCINE RICH REPEAT CONTAINING 2 PROTEIN; LEUCINE ZIPPER PROTEIN 3; LEUCINE ZIPPER PROTEIN PSEUDOGENE 1; LEUCINE ZIPPER TRANSCRIPTION FACTOR LIKE 1 PROTEIN; LIM DOMAIN CONTAINING GENE 1 PROTEIN; PROTEIN; RANTES; RETINOBLASTOMA PROTEIN; SEMAPHORIN; TRANSMEMBRANE PROTEIN 7; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALLELIC IMBALANCE; APOPTOSIS; ARTIFICIAL CHROMOSOME; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENICITY; CELL CYCLE; CHROMOSOME 3; CHROMOSOME 3P; CHROMOSOME 3Q; CHROMOSOME BAND; CHROMOSOME DELETION; CLEAR CELL CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; GENE IDENTIFICATION; GENE ISOLATION; GENE MAPPING; GENE MUTATION; GENETIC MARKER; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; LUNG SMALL CELL CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETINOBLASTOMA; REVIEW; TUMOR SUPPRESSOR GENE;

GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; RETINOBLASTOMA PROTEIN;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0344412836     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.10271     Document Type: Review

References (91)

1. Acevedo CM, Henriquez M, Emmert-Buck MR, Chuaqui RF. 2002. Loss of heterozygosity on chromosome arms 3p and 6q in microdissected adenocarcinomas of the uterine cervix and adenocarcinoma in situ. Cancer 94:793-802.
2. Ahuja SK, Lee JC, Murphy PM. 1996. CXC chemokines bind to unique sets of selectivity determinants that can function independently and are broadly distributed on multiple domains of human interleukin-8 receptor B. Determinants of high affinity binding and receptor activation are distinct. J Biol Chem 271:225-232.
3. Alimov A, Kost-Alimova M, Liu J, Li C, Bergerheim U, Imreh S, Klein G, Zabarovsky ER. 2000. Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma. Oncogene 19:1392-1399.
4. Andersson MJ, Stanbridge EJ. 1993. Tumor suppressor genes studied by cell hybridization and chromosome transfer. FASEB J 7:826-833.
5. Bezault J, Bhimani R, Wiprovnick J, Furmanski P. 1994. Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res 54:2310-2312.
6. Boldog F, Arheden K, Imreh S, Strombeck B, Szekely L, Erlandsson R, Marcsek Z, Sumegi J, Mitelman F, Klein G. 1941. Involvement of 3p deletions in sporadic and hereditary forms of renal cell carcinoma. Genes Chromosomes Cancer 3:403-406.
7. Braga E, Pugacheva E, Basov I, Ermilova V, Kazubskaya T, Mazurenko N, Kisseljov F, Liu J, Garkavtseva R, Debabov V, Zabarovsky E, Kisselev, L. 1999. Allelotyping of human chromosome 3p in four types of malignant epithelial tumors using di-, tri- and tetrameric markers. FEBS Lett 454:215-219.
8. Braga E, Sentchenko V, Bazov I, Loginov W, Liu J, Ermilova V, Kazubskaya T, Garkavtseva R, Mazurenko N, Kisseljov F, Lerman MI, Klein G, Kisselev L, Zabarovsky ER. 2002. Critical TSG regions on chromosome 3p in major human epithelial malignancies: allelotyping and quantitative real-time PCR. Int J Cancer 100:534-541.
9. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD. 2001. RASSF1A in the 3p21.3 homozygous deletion region: epigenetic inactivation in lung and breast cancer and suppression of the malignant phenotype. J Natl Cancer Inst 93:691-699.
10. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL. 1983. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305:779-784.
11. Cutler ML, Bassin RH, Zanoni L, Talbot N. 1992. Isolation of rsp-1, a novel cDNA capable of suppressing v-Ras transformation. Mol Cell Biol 12:3750-3756.
12. Daigo Y, Nishiwaki T, Kawasoe T, Tamari M, Tsuchiya E, Nakamura Y. 1999. Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3. Cancer Res 59:1966-1972.
13. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. 2000. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25:315-319.
14. Davis LM, Caspary WJ, Sakallah SA, Maronpot R, Wiseman R, Barrett JC, Elliott R, Hozier JC. 1994. Loss of heterozygosity in spontaneous and chemically induced tumors of the B6C3F1 mouse. Carcinogenesis 15:1637-1645.
15. Dietrich WF, Radany EH, Smith JS, Bishop JM, Hanahan D, Lander ES. 1994. Genome-wide search for loss of heterozygosity in transgenic mouse tumors reveals candidate tumor suppressor genes on chromosomes 9 and 16. Proc Natl Acad Sci USA 91:9451-9455.
16. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov, A, Li J, Kashuba V, Klein G, Zabarovsky ER. 2001. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA 98:7504-7509.
17. Erlandsson R, Boldog F, Sumegi J, Klein G. 1988. Do human renal cell carcinomas arise by a double-loss mechanism? Cancer Genet Cytogenet 36:197-202.
18. Fioretti F, Fradelizi D, Stoppacciaro A, Ramponi S, Ruco L, Minty A, Sozzani S, Garlanda C, Vecchi A, Mantovani A. 1998. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J Immunol 161:342-346.
19. Fujisawa H, Kitsukawa T. 1998. Receptors for collapsin/semaphorins. Curr Opin Neurobiol 8:587-592.
20. Harris H, Miller OJ, Klein G, Worst P, Tachibana T. 1969. Suppression of malignancy by cell fusion. Nature 223:363-368.
21. Helland A, Kraggerud SM, Kristensen GB, Holm R, Abeler VM, Huebner K, Borresen-Dale AL, Lothe RA. 2000. Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival. Int J Cancer 88:217-222.
22. Heng HH. 2000. Released chromatin or DNA fiber preparations for high-resolution fiber FISH. Methods Mol Biol 123:69-81.
23. Herzog CR, Crist KA, Sabourin CL, Kelloff GJ, Boone CN, Stoner GD, You M. 2001. Chromosome 3p tumor-suppressor gene alterations in cervical carcinomas. Mol Carcinog 30:159-168.
24. Heston WE. 1963. Genetics of neoplasia. In: Burdette WJ, editor. Methodology in mammalian genetics. San Francisco: Holden-Day, p 247-268.
25. Hodgson G, Hager JH, Volik S, Hariono S, Wernick M, Moore D, Nowak N, Albertson DG, Pinkel D, Collins C, Hanahan D, Gray JW. 2001. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet 29:459-464.
26. Hu LF, Eiriksdottir G, Lebedeva T, Kholodniouk I, Alimov A, Chen F, Luo Y, Zabarovsky ER, Ingvarsson S, Klein G, Ernberg I. 1996. Loss of heterozygosity on chromosome arm 3p in nasopharyngeal carcinoma. Genes Chromosomes Cancer 17:118-126.
27. Imreh S, Kholodyuk I, Allikmetts R, Stanbridge EJ, Zabarovsky ER, Klein G. 1994. Nonrandom loss of human chromosome 3 fragments from mouse-human microcell hybrids following progressive growth in SCID mice. Genes Chromosomes Cancer 11:237-245.
28. Imreh S, Kost-Alimova M, Kholodnyuk I, Yang Y, Szeles A, Kiss H, Stanbridge E, Klein G. 1997. Differential elimination 3p/3q segments of human/mouse microcell hybrids during tumor growth. Genes Chromosomes Cancer 20:224-233.
29. Ishikawa S, Kai M, Tamari M, Takei Y, Takeuchi K, Bandou H, Yamane Y, Ogawa M, Nakamura Y. 1997. Sequence analysis of a 685-kb genomic region on chromosome 3p22-p21.3 that is homozygously deleted in a lung carcinoma cell line. DNA Res 41:35-43.
30. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y, Minna J, Borodovsky A, Schultz DC, Wilkinson KD, Maul GG, Barlev N, Berger SL, Prendergast GC, Rauscher FJ 3rd. 1998. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16:1097-1112.
31. Kholodnyuk I, Kost-Alimova M, Kashuba V, Szeles A, Stanbridge EJ, Zabarovsky ER, Klein G, Imreh S. 1997. A 3p21.3 region is preferentially eliminated from human chromosome 3/mouse microcell hybrids during tumor growth in SCID mice. Genes Chromosomes Cancer 18:200-211.
32. Kholodnyuk I, Szeles A, Yang Y, Klein G, Imreh S. 2000. Inactivation of the human FHIT gene at 3p14.2 in monochromosomal human/mouse microcell hybrid derived SCID tumors. Cancer Res 60:7119-7125.
33. Kholodnyuk ID, Kost-Alimova M, Yang Y, Kiss H, Fedorova L, Klein G, Imreh S. 2002. The microcell hybrid based "elimination test" identifies a 1-Mb putative tumor suppressor region at 3p22.2-p22.1 centromeric to the homozygous deletion region detected in lung cancer. Genes Chromosomes Cancer 34:341-344.
34. Killary AM, Wolf ME, Giambernardi TA, Naylor SL. 1992. Definition of a tumor suppressor locus within human chromosome 3p21-p22. Proc Natl Acad Sci USA 89:10877-10881.
35. Kiss H, Kedra D, Yang Y, Kost-Alimova M, Kiss CS, O'Brien K, Fransson I, Klein G, Imreh S, Dumanski JP. 1999. A novel gene containing LIM domains (LIMD1) is located within the common eliminated region 1 (C3CER1) in 3p21.3. Hum Genet 105:555-559.
36. Kiss H, Kedra D, Yang Y, Kost-Alimova M, Kiss CS, O'Brien K, Fransson I, Klein G, Imreh S, Dumanski JP. 2001. The LZTFL1 gene is a part of a transcriptional map covering 250 kb within the common eliminated region 1 (C3GER1) in 3p21.3. Genomics 73:10-19.
37. Kiss H, Yang Y, Kiss C, Andersson K, Klein G, Imreh S, Dumanski JP. 2002. The transcriptional map of the common eliminated region (C3CER1) in 3p21.3. Eur J Hum Genet 10:52-61.
38. Kiss, H, Darai E, Kiss CS, Kost-Alimova M, Klein G, Dumanski JP, Imreh S. 2003. Comparative human/murine sequence analysis of the common eliminated region 1 from human 3p21.3. Mamm Genome 13:646-655.
39. Klein G. 1987. The approaching era of the tumor suppressor genes. Science 238:1539-1545.
40. Klein G. 2001. Are there large uncharted regions of tumor suppressor genes? IUBMB Life 51:83-85.
41. Knudson AG. 1971. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823.
42. Knudson AG. 2001. Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157-170.
43. Kok K, Naylor SL, Buys CH. 1997. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res 71:27-92.
44. Kost-Alimova M, Kiss H, Fedorova L, Yang Y, Dumanski JP, Klein G, Imreh S. 2003. The coincidence of synteny breakpoints with malignancy related deletions, Proc Natl Acad Sci USA 100:6622-6627.
45. Kovacs G, Erlandsson R, Boldog F, Ingvarsson S, Muller-Brechlin R, Klein G, Sumegi J. 1988. Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci USA 85:1571-1575.
46. Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, Vocke CD, Duh FM, Zabarovsky E, Minna JD, Rhim JS, Emmert-Buck MR, Linehan WM, Lerman MI. 2002. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 62:3498-3502.
47. Lerman MI, Minna JD, The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. 2000. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. Cancer Res 60:6116-6133.
48. Li J, Protopopov AI, Gizatullin RZ, Kiss C, Kashuba VI, Winberg G, Klein G, Zabarovsky ER. 1999. Identification of new tumour suppressor genes based on in vivo functional inactivation of a candidate gene. FEBS Lett 451:289-294.
49. Li J, Protopopov A, Wang F, Sentchenko V, Petushkov V, Vorontsova O, Petrenko L, Zabarovska V, Muravenko O, Braga E, Kisselev L, Lerman MI, Kashuba V, Klein G, Ernberg I, Wahlestedt C, Zabarovsky ER. 2002. NotI subtraction and NotI-specific microarrays to detect copy number and methylation changes in whole genomes. Proc Natl Acad Sci USA 99:10724-10729.
50. Linardopoulos S, Silva S, Klein G, Balmain A. 2000. Allele-specific loss or imbalance of chromosomes 9, 15, and 16 in B-cell tumors from interspecific F1 hybrid mice carrying Emu-c-myc of N-myc transgenes. Int J Cancer 88:920-927.
51. Liu J, Zabarovska V, Braga E, Alimov A, Klein G, Zabarovsky ER. 1999. Loss of heterozygosity in tumor cells requires re-evaluation: the data are biased by the size-dependent differential sensitivity of allele detection. FEBS Lett 462:121-128.
52. Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, Teo PM, Johnson PJ, Huang DP. 2001. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 61:3877-3881.
53. Maitra A, Wistuba II, Washington C, Virmani AK, Ashfaq R, Milchgrub S, Gazdar AF, Minna JD. 2001. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol 159:119-130.
54. Mitelman F. 2000. Recurrent chromosome aberrations in cancer. Mutat Res 462:247-253.
55. Mitelman F, Mertens F, Johansson B. 1997. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 15:417-474.
56. Mitelman's catalog of chromosome aberrations in cancer. May be accessed at http:/www.wiley.com/legacy/products/subject/life/mitelman/index.htm.
57. Muller CY, O'Boyle JD, Fong KM, Wistuba II, Biesterveld E, Ahmadian M, Miller DS, Gazdar AF, Minna JD. 1998. Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: association with human papillomavirus type. J Natl Cancer Inst 90:433-439.
58. Murata Y, Tamari M, Takahashi T, Horio Y, Hibi K, Yokoyama S, Inazawa J, Yamakawa K, Ogawa A, Takahashi T. 1994. Characterization of an 800 kb region at 3p22-p21.3 that was homozygously deleted in a lung cancer cell line. Hum Mol Genet 3:1341-1344.
59. Norrby K, Mattsby-Baltzer I, Innocenti M, Tuneberg S. 2001. Orally administered bovine lactoferrin systemically inhibits VEGF(165)-mediated angiogenesis in the rat. Int J Cancer 91:236-240.
60. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, Avruch J. 2002. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 21:1381-1390.
61. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. 2002. FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol 3:748-754.
62. Protopopov AI, Li J, Winberg G, Gizatullin RZ, Kashuba VI, Klein G, Zabarovsky ER. 2002. Human cell lines engineered for tetracycline-regulated expression of tumor suppressor candidate genes from a frequently affected chromosomal region, 3p21. J Gene Med 4:397-406.
63. Protopopov AI, Kashuba VI, Zabarovska VI, Muravenko OV, Letman MI, Klein G, Zabarovsky ER. 2003. An integrated physical and gene map of the 3.5-Mb chromosome 3p21.3 (AP20) region implicated in major human epithelial malignancies. Cancer Res 63:404-412.
64. Roche J, Boldog F, Robinson M, Robinson L, Varella-Garcia M, Swanton M, Waggoner B, Fishel R, Franklin W, Gemmill R, Drabkin H. 1996. Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 12:1289-1297.
65. Rothberg JM, Jacobs JR, Goodman CS, Artavanis-Tsakonas S. 1990. Slit: an extracellular protein necessary for development of midline glia and commissural axon pathways contains both EGF and LRR domains. Genes Dev 4:2169-2187.
66. Saxon PJ, Stanbridge EJ. 1987. Transfer and selective retention of single specific human chromosomes via microcell mediated chromosome transfer. In: Gottesman MM, editor. Methods in enzymology (Vol. 151), p 313-320. Academic Press.
67. Sekido Y, Ahmadian M, Wistuba II, Latif F, Bader S, Wei MH, Duh FM, Gazdar AF, Lerman MI, Minna JD. 1998. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene 16:3151-3157.
68. Sentchenko V, Liu J, Braga E, Mazurenko N, Loginov W, Seryogin Y, Bazov I, Protopopov A, Kiseljov F, Kashuba V, Lerman MI, Klein G, Zabarovsky E. 2003. Deletion mapping using quantitative real-time PCR identifies two distinct 3p21. 3 regions affected in most cervical carcinomas. Oncogene 22:2984-2992.
69. Shigemitsu K, Sekido Y, Usami N, Mori S, Sato M, Horio Y, Hasegawa Y, Bader SA, Gazdar AF, Minna JD, Hida T, Yoshioka H, Imaizumi M, Ueda Y, Takahashi NI, Shimokata K. 2001. Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene 20:4249-4257.
70. Shimizu M, Yokota J, Mori N, Shuin T, Shinoda M, Terada M, Oshimura M. 1990. Introduction of normal chromosome 3p modulates the tumorigenicity of a human renal cell carcinoma cell line YCR. Oncogene 5:185-194.
71. Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA. 2002. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 22:4309-4318.
72. Siebert PD, Huang BC. 1997. Identification of an alternative form of human lactoferrin mRNA that is expressed differentially in normal tissues and tumor-derived cell lines. Proc Natl Acad Sci USA 94:2198-2203.
73. Stenmark H, Aasland R. 1999. FYVE-finger proteins-effectors of an inositol lipid. J Cell Sci 112:4175-4183.
74. Su YA, Lee MM, Hutter CM, Meltzer PS. 1997. Characterization of a highly conserved gene (OS4) amplified with CDK4 in human sarcomas. Oncogene 15:1289-1294.
75. Szeles A, Yang Y, Sandlund A, Kost-Alimova M, Kholodnyuk I, Kiss H, Kost-Alimova M, Zabarovsky E, Stanbridge E, Klein G, Imreh S. 1997. Human/mouse microcell hybrid based elimination test reduces the putative tumor suppressor region to 1.6 cM. Genes Chromosomes Cancer 20:329-336.
76. Tomizawa Y, Sekido Y, Kondo M, Gao B, Yokota J, Roche J, Drabkin H, Lerman MI, Gazdar AF, Minna JD. 2001. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci USA 98:13954-13959.
77. Trusolino L, Comoglio PM. 2002. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2:289-300.
78. Ushida Y, Sekine K, Kuhara T, Takasuka N, Iigo M, Tsuda H. 1998. Inhibitory effects of bovine lactoferrin on intestinal polyposis in the Apc(Min) mouse. Cancer Lett 134:141-145.
79. Ushida Y, Sekine K, Kuhara T, Takasuka N, Iigo M, Maeda M, Tsuda H. 1999. Possible chemopreventive effects of bovine lactoferrin on esophagus and lung carcinogenesis in the rat. Jpn J Cancer Res 90:262-267.
80. Vos MD, Ellis CA, Bell A, Bitter MJ, Clark GJ. 2000. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 275:35669-35672.
81. Wang L, Darling J, Zhang JS, Liu W, Qian J, Bostwick D, Hartmann L, Jenkins R, Bardenhauer W, Schutte J, Opalka B, Smith DI. 2000. Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma. Genes Chromosomes Cancer 1:1-10.
82. Wei MH, Latif F, Bader S, Kashuba V, Chen JY, Duh FM, Sekido Y, Lee CC, Geil L, Kuzmin I, Zabarovsky E, Klein G, Zbar B, Minna JD, Lerman MI. 1996. Construction of a 600-kilobase cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3: progress toward the isolation of a lung cancer TSG. Cancer Res 56:1487-1492.
83. Wistuba II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, Chen H, Ahmadian M, Nowak JA, Muller C, Minna JD, Gazdar AF. 1997. Deletions of chromosome 3p ate frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res 57:3154-3158.
84. Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon JW 3rd, Garner HR, McKay B, Latif F, Lerman MI, Lam S, Gazdar AF, Minna JD. 2000. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p. Allele loss and three regions of frequent breakpoints. Cancer Res 60:1949-1960.
85. Yang Y, Kiss H, Kost-Alimova M, Kedra D, Franssson I, Seroussi E, Li J, Szeles A, Kholodnyuk I, Imreh MP, Fodor K, Hadlaczky Gy, Klein G, Dumanski JP, Imreh S. 1999, A 1-Mb PAC contig spanning the common eliminated region 1 (CER1) in microcell hybrid-derived SCID tumors. Genomics 62:147-157.
86. Yang Y, Alimova MK, Ingvarsson S, Qianhui Q, Kiss H, Szeles A, Cuthbert A, Klein G, Imreh S. 2001. "Elimination test (Et)" identifies similar 3p regions, including CER1 at 3p21.3, in the human/human and in human/mouse microcell hybrid derived tumors. Proc Natl Acad Sci USA 98:1136-1141.
87. Yang Y, Li JF, Szeles A, Imreh MP, Kost-Alimova M, Kholodnyuk I, Fedorova L, Darai E, Klein G, Imreh S. 2003. Consistent downregulation of human lactoferrin (LF) gene expressed in A9 murine fibrosarcoma cells, following tumor growth in SCID mice. Cancer Lett 191:155-164.
88. Yoo YC, Watanabe R, Koike Y, Mitobe M, Shimazaki K, Watanabe S, Azuma I. 1997. Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: involvement of reactive oxygen species. Biochem Biophys Res Commun 237:624-628.
89. Yoo YC, Watanabe S, Watanabe R, Hata K, Shimazaki K, Azuma I. 1998. Bovine lactoferrin and lactoferricin inhibit tumor metastasis in mice. Adv Exp Med Biol 443:285-291.
90. Zabarovsky ER, Lerman MI, Minna JD. 2002. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21:6915-6935.
91. Zhang L, Underhill CB, Chen L. 1995. Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res 55:428-433.